Business Context and Reporting Period
Company: Bristol-Myers Squibb Company
Filing Type: Form 8-K (Current Report)
Date of Report: September 9, 2008
Subject: Amendments to Articles of Incorporation or Bylaws (Item 5.03)
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report is strictly administrative regarding corporate governance.
Material Changes
The Board of Directors amended the Company's Bylaws on September 9, 2008, to reflect recent statutory and case law developments. Key changes include:
- Bylaw 4 (Advance Notice): Revised to clarify guidelines for stockholder business and director nominations. The notice window is now 90-120 days pegged to the anniversary of the preceding year's annual meeting. Stockholders must describe any arrangements or agreements regarding nominations.
- Bylaw 23 (Indemnification): Made the advancement of expenses mandatory. Clarified that repeal/modification does not eliminate protections for prior acts and allows directors/officers to sue for unpaid indemnification.
- Bylaw 25(d): Affirmatively opted into Section 141(c)(2) of the Delaware General Corporation Law.
- Bylaw 31 (Resignation): Limited officer resignations to written notice only.
- Bylaw 44 (Borrowing): Changed "corporation" to "entity" to reflect alternate borrowing sources.
- Bylaw 47 (Signatures): Allowed facsimile signatures on stock certificates.
- Bylaw 53 (Notice by Mail): Clarified mailing procedures.
- Bylaw 54 (Householding): Added to allow single copies of notices for stockholders sharing an address.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management outlook, risk factors, or discussion of unusual items. The stated intent of the amendments is to foreclose potential disputes, enhance the Board's ability to prepare for meetings, and safeguard stockholder rights.
Key Facts for Investor Verification
- Verify the effective date of the new Bylaws (September 9, 2008) against the company's proxy materials.
- Review the specific 90-120 day notice window for stockholder proposals to ensure compliance for future meetings.
- Confirm the mandatory nature of expense advancement for directors and officers under the new Bylaw 23.
- Check the attached Exhibit 3.1 for the full text of the revised Bylaws.